Rifabutin loaded inhalable β-glucan microparticle based drug delivery system for pulmonary TB.
Alveolar macrophages
Anti- TB drug delivery
Rifabutin
β-Glucan particles
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 Jul 2024
16 Jul 2024
Historique:
received:
22
03
2024
accepted:
03
07
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
16
7
2024
Statut:
epublish
Résumé
Inhalable microparticle-based anti TB drug delivery systems are being investigated extensively for Tuberculosis [TB] treatment as they offer efficient and deep lung deposition with several advantages over conventional routes. It can reduce the drug dose, treatment duration and toxic effects and optimize the drug bioavailability. Yeast derived β-glucan is a β-[1-3/1-6] linked biocompatible polymer and used as carrier for various biomolecules. Due to presence of glucan chains, particulate glucans act as PAMP and thereby gets internalized via receptor mediated phagocytosis by the macrophages. In this study, β-glucan microparticles were prepared by adding l-leucine as excipient, and exhibited 70% drug [Rifabutin] loading efficiency. Further, the sizing and SEM data of particles revealed a size of 2-4 µm with spherical dimensions. The FTIR and HPLC data confirmed the β-glucan composition and drug encapsulations efficiency of the particles. The mass median aerodynamic diameter [MMAD] and geometric standard deviation [GSD] data indicated that these particles are inhalable in nature and have better thermal stability as per DSC thermogram. These particles were found to be non-toxic upto a concentration of 80 µg/ml and were found to be readily phagocytosed by human macrophage cells in-vitro as well as in-vivo by lung alveolar macrophage. This study provides a framework for future design of inhalable β-glucan particle based host-directed drug delivery system against pulmonary TB.
Identifiants
pubmed: 39013991
doi: 10.1038/s41598-024-66634-5
pii: 10.1038/s41598-024-66634-5
doi:
Substances chimiques
Rifabutin
1W306TDA6S
beta-Glucans
0
Drug Carriers
0
Antitubercular Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16437Subventions
Organisme : Irfan Ahmad Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia; Email: irfancsmmu@gmail.com
ID : Small Research Group Project under Grant no. [R.G.P.1/226/44]
Organisme : Irfan Ahmad Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia; Email: irfancsmmu@gmail.com
ID : Small Research Group Project under Grant no. [R.G.P.1/226/44]
Organisme : Irfan Ahmad Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia; Email: irfancsmmu@gmail.com
ID : Small Research Group Project under Grant no. [R.G.P.1/226/44]
Organisme : Irfan Ahmad Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia; Email: irfancsmmu@gmail.com
ID : Small Research Group Project under Grant no. [R.G.P.1/226/44]
Organisme : Irfan Ahmad Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia; Email: irfancsmmu@gmail.com
ID : Small Research Group Project under Grant no. [R.G.P.1/226/44]
Organisme : Irfan Ahmad Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia; Email: irfancsmmu@gmail.com
ID : Small Research Group Project under Grant no. [R.G.P.1/226/44]
Organisme : Irfan Ahmad Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia; Email: irfancsmmu@gmail.com
ID : Small Research Group Project under Grant no. [R.G.P.1/226/44]
Organisme : Irfan Ahmad Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia; Email: irfancsmmu@gmail.com
ID : Small Research Group Project under Grant no. [R.G.P.1/226/44]
Organisme : Irfan Ahmad Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia; Email: irfancsmmu@gmail.com
ID : Small Research Group Project under Grant no. [R.G.P.1/226/44]
Organisme : Irfan Ahmad Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia; Email: irfancsmmu@gmail.com
ID : Small Research Group Project under Grant no. [R.G.P.1/226/44]
Informations de copyright
© 2024. The Author(s).
Références
Jeremiah, C. et al. The WHO global tuberculosis 2021 report—Not so good news and turning the tide back to end TB. Int. J. Infect. Dis. IJID https://doi.org/10.1016/j.ijid.2022.03.011 (2022).
doi: 10.1016/j.ijid.2022.03.011
Sotgiu, G., Sulis, G. & Matteelli, A. Tuberculosis-a world health organization perspective. Microbiol. Spectr. https://doi.org/10.1128/microbiolspec.TNMI7-0036-2016 (2017).
doi: 10.1128/microbiolspec.TNMI7-0036-2016
pubmed: 28185618
Firoz, Ahmad et al. Recent advances in nano-carrier based therapeutic and diagnostic approaches in mycobacterium tuberculosis. Precis. Nanomed. https://doi.org/10.33218/001c.906995 (2023).
doi: 10.33218/001c.906995
Mujeeb, S., Singh, K., Yogi, B., Ansari, V. & Sinha, S. A review on coumarin derivatives as potent anti-tuberculosis agents. Mini. Rev. Med. Chem. 22(7), 1064–1080. https://doi.org/10.2174/138955752166621092712451 (2022).
doi: 10.2174/138955752166621092712451
pubmed: 34579635
Forget, E. J. & Menzies, D. Adverse reactions to first-line antituberculosis drugs. Expert Opin. Drug Saf. 5(2), 231–249. https://doi.org/10.1517/14740338.5.2.231 (2006).
doi: 10.1517/14740338.5.2.231
pubmed: 16503745
Singh, R. et al. Recent updates on drug resistance in Mycobacterium tuberculosis. J. Appl. Microbiol. 128(6), 1547–1567. https://doi.org/10.1111/jam.14478 (2020).
doi: 10.1111/jam.14478
pubmed: 31595643
Brown, G. D. & Gordon, S. Fungal beta-glucans and mammalian immunity. Immunity 19(3), 311–315. https://doi.org/10.1016/s1074-7613[03]00233-4 (2003).
doi: 10.1016/s1074-7613[03]00233-4
pubmed: 14499107
Pai, R. V., Jain, R. R., Bannalikar, A. S. & Menon, M. D. Development and evaluation of chitosan microparticles based dry powder inhalation formulations of rifampicin and rifabutin. J. Aerosol Med. Pulm. Drug deliv. 29(2), 179–195. https://doi.org/10.1089/jamp.2014.1187 (2016).
doi: 10.1089/jamp.2014.1187
pubmed: 26406162
Ahmad, F. et al. β-glucan primed and DYDGP microparticles treatment induces trained immunity against mycobacterium tuberculosis infected human macrophage: an in-vitro/in-vivo studies, 14 May 2024, Preprint (Version 1) available at Research Square. https://doi.org/10.21203/rs.3.rs-4355029/v1
Soto, E. R. & Ostroff, G. R. Characterization of multilayered nanoparticles encapsulated in yeast cell wall particles for DNA delivery. Bioconjugate Chem. 19(4), 840–848. https://doi.org/10.1021/bc700329p (2008).
doi: 10.1021/bc700329p
Soto, E., Kim, Y. S., Lee, J., Kornfeld, H. & Ostroff, G. Glucan particle encapsulated rifampicin for targeted delivery to macrophages. Polymers 2, 681–689 (2010).
doi: 10.3390/polym2040681
Upadhyay, T. K., Fatima, N., Sharma, D., Saravanakumar, V. & Sharma, R. Preparation and characterization of beta-glucan particles containing a payload of nanoembedded rifabutin for enhanced targeted delivery to macrophages. EXCLI J. 6, 210–228. https://doi.org/10.17179/excli2016-804 (2017).
doi: 10.17179/excli2016-804
Yu, C. et al. β-Glucan from Saccharomyces cerevisiae alleviates oxidative stress in LPS-stimulated RAW264.7 cells via Dectin-1/Nrf2/HO-1 signaling pathway. Cell Stress Chaperones 26(4), 629–637. https://doi.org/10.1007/s12192-021-01205-5 (2021).
doi: 10.1007/s12192-021-01205-5
pubmed: 33880723
pmcid: 8275741
Soto, E. R., Caras, A. C., Kut, L. C., Castle, M. K. & Ostroff, G. R. Glucan particles for macrophage targeted delivery of nanoparticles. J. Drug Deliv. 2012, 143524. https://doi.org/10.1155/2012/143524 (2012).
doi: 10.1155/2012/143524
pubmed: 22013535
Islam, M. S. et al. Polydisperse microparticle transport and deposition to the terminal bronchioles in a heterogeneous vasculature tree. Sci. Rep. 8(1), 16387. https://doi.org/10.1038/s41598-018-34804-x (2018).
doi: 10.1038/s41598-018-34804-x
pubmed: 30401963
pmcid: 6219544
Lee, W. H., Loo, C. Y., Traini, D. & Young, P. M. Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages. Exp. Opin. Drug Deliv. 12(6), 1009–1026. https://doi.org/10.1517/17425247.2015.1039509 (2015).
doi: 10.1517/17425247.2015.1039509
Xiong, M. H., Bao, Y., Yang, X. Z., Zhu, Y. H. & Wang, J. Delivery of antibiotics with polymeric particles. Adv. Drug Deliv. Rev. 78, 63–76. https://doi.org/10.1016/j.addr.2014.02.002 (2014).
doi: 10.1016/j.addr.2014.02.002
pubmed: 24548540
Healy, A. M., Amaro, M. I., Paluch, K. J. & Tajber, L. Dry powders for oral inhalation free of lactose carrier particles. Adv. Drug Deliv. Rev. 75, 32–52. https://doi.org/10.1016/j.addr.2014.04.005 (2014).
doi: 10.1016/j.addr.2014.04.005
pubmed: 24735676
Muttil, P. et al. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 32(2), 140–50. https://doi.org/10.1016/j.ejps.2007.06.006 (2007).
doi: 10.1016/j.ejps.2007.06.006
pubmed: 17681458
Dabbagh, A., Abu Kasim, N. H., Yeong, C. H., Wong, T. W. & Abdul Rahman, N. Critical parameters for particle-based pulmonary delivery of chemotherapeutics. J. aerosol medicine and pulmonary drug delivery 31(3), 139–154. https://doi.org/10.1089/jamp.2017.1382 (2018).
doi: 10.1089/jamp.2017.1382
pubmed: 29022837
Finlay, W. H. The Mechanics of Inhaled Pharmaceutical Aerosols: An Introduction 2nd edn. (Elsevier, 2019).
Darquenne, C. Deposition Mechanisms. J. Aerosol Med. Pulm. Drug Deliv. 33(4), 181–185. https://doi.org/10.1089/jamp.2020.29029.cd (2020).
doi: 10.1089/jamp.2020.29029.cd
pubmed: 32598200
Hickey, A. J., Misra, A. & Fourie, P. B. Dry powder antibiotic aerosol product development: Inhaled therapy for tuberculosis. J. Pharm. Sci. 102(11), 3900–3907. https://doi.org/10.1002/jps.23705 (2013).
doi: 10.1002/jps.23705
pubmed: 23963705
Ahmad, Z., Sharma, S. & Khuller, G. K. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents 26(4), 298–303. https://doi.org/10.1016/j.ijantimicag.2005.07.012 (2005).
doi: 10.1016/j.ijantimicag.2005.07.012
pubmed: 16154726
Sharma, R., Saxena, D., Dwivedi, A. K. & Misra, A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 18(10), 1405–1410. https://doi.org/10.1023/a:1012296604685 (2001).
doi: 10.1023/a:1012296604685
pubmed: 11697465
Ordoubadi, M. et al. Multi-solvent microdroplet evaporation: Modeling and measurement of spray-drying kinetics with inhalable pharmaceutics. Pharm. Res. 36(7), 100. https://doi.org/10.1007/s11095-019-2630-7 (2019).
doi: 10.1007/s11095-019-2630-7
pubmed: 31089892
Ordoubadi, M. et al. On the particle formation of leucine in spray drying of inhalable microparticles. Int. J. Pharm. 592, 120102. https://doi.org/10.1016/j.ijpharm.2020.120102 (2021).
doi: 10.1016/j.ijpharm.2020.120102
pubmed: 33227375
Lechuga-Ballesteros, D., Hoe, S. & Maynor, B. W. Particle engineering technology for inhaled therapies. In Pharmaceutical Inhalation Aerosol Technology (eds Hickey, A. J. & da Rocha, S. R. P.) 349–361 (CRC Press, Boca Raton, 2019). https://doi.org/10.1201/9780429055201 .
doi: 10.1201/9780429055201
Mah, P. T. et al. The use of hydrophobic amino acids in protecting spray dried trehalose formulations against moisture-induced changes. Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahr. e.V 144, 139–153. https://doi.org/10.1016/j.ejpb.2019.09.014 (2019).
doi: 10.1016/j.ejpb.2019.09.014
Li, L. et al. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders. Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahr. e.V 102, 132–141. https://doi.org/10.1016/j.ejpb.2016.02.010 (2016).
doi: 10.1016/j.ejpb.2016.02.010
Zechner-Krpan, V. et al. Characterization of β-glucans isolated from brewer’s yeast and dried by diff meth. Food Technol. Biotech. 48, 189–197 (2010).
Hromadkova, Z. et al. Influence of the drying method on the physical properties and immunomodulatory activity of the particulate [1→3]-β-D-glucan from Saccharomyces cerevisiae. Carbohydr. Polym. 51, 9–15 (2003).
doi: 10.1016/S0144-8617(02)00110-8
Nighute, A. B. & Bhise, S. B. Preparation and evaluation of rifabutin loaded polymeric microspheres. Res. J. Pharm. Tech 2(2), 371–374 (2009).
Fatima, N. et al. Particulate β-glucan activates early and delayed phagosomal maturation and autophagy within macrophage in a NOX-2 dependent manner. Life Sci. 266, 118851. https://doi.org/10.1016/j.lfs.2020.118851 (2021).
doi: 10.1016/j.lfs.2020.118851
pubmed: 33310032
Vetvicka, V. Glucan-immunostimulant, adjuvant, potential drug. World J. Clin. Oncol. 2, 115. https://doi.org/10.5306/wjco.v2.i2.115 (2011).
doi: 10.5306/wjco.v2.i2.115
pubmed: 21603320
pmcid: 3095473
Yan, J. et al. β-Glucan, a “specific” biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J. Immunol. 163, 3045–3052. https://doi.org/10.4049/jimmunol.163.6.3045 (1999).
doi: 10.4049/jimmunol.163.6.3045
pubmed: 10477568
Tian, X. et al. Particulate β-glucan regulates the immunosuppression of granulocytic myeloid-derived suppressor cells by inhibiting NFIA expression. Oncoimmunology 4, e1038687. https://doi.org/10.1080/2162402X.2015.1038687 (2015).
doi: 10.1080/2162402X.2015.1038687
pubmed: 26405609
pmcid: 4570107
Carrigy, N. B. et al. Amorphous pullulan trehalose microparticle platform for respiratory delivery. Int. J. Pharm. 563, 156–168. https://doi.org/10.1016/j.ijpharm.2019.04.004 (2019).
doi: 10.1016/j.ijpharm.2019.04.004
pubmed: 30951858
Eedara, B. B., Rangnekar, B., Doyle, C., Cavallaro, A. & Das, S. C. The influence of surface active l-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine [DPPC] in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders. Int. J. Pharm. 542(1–2), 72–81. https://doi.org/10.1016/j.ijpharm.2018.03.005 (2018).
doi: 10.1016/j.ijpharm.2018.03.005
pubmed: 29524618
Bacha, U., Nasir, M., Iqbal, S. & Anjum, A. A. Nutraceutical, Anti-Inflammatory, and Immune Modulatory Effects of β-Glucan Isolated from Yeast. BioMed Res. Int. 2017, 8972678. https://doi.org/10.1155/2017/8972678 (2017).
doi: 10.1155/2017/8972678
pubmed: 28913359
pmcid: 5587958
Heyder, J. & Gebhart, J. Gravitational deposition of particles from laminar aerosol flow through inclined circular tubes. J. Aerosol Sci. 8(4), 289–295 (1977).
doi: 10.1016/0021-8502(77)90048-9
Gaspar, D. P. et al. Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies. Int. J. Pharm. 497(1–2), 199–209. https://doi.org/10.1016/j.ijpharm.2015.11.050 (2016).
doi: 10.1016/j.ijpharm.2015.11.050
pubmed: 26656946
Alves, A. D. et al. Inhalable antitubercular therapy mediated by locust bean gum microparticles. Molecules 21(6), 702. https://doi.org/10.3390/molecules21060702 (2016).
doi: 10.3390/molecules21060702
pubmed: 27240337
pmcid: 6273308
Ranjan, R. et al. Preparation and optimization of a dry powder for inhalation of second-line anti-tuberculosis drugs. Int. J. Pharm. 547(1–2), 150–157. https://doi.org/10.1016/j.ijpharm.2018.05.065 (2018).
doi: 10.1016/j.ijpharm.2018.05.065
pubmed: 29852204
Todoroff, J. et al. Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85 A following its co-delivery with CpG, MPLA or LTB to the lungs in mice. PloS one 8(5), e63344. https://doi.org/10.1371/journal.pone.0063344 (2013).
doi: 10.1371/journal.pone.0063344
pubmed: 23675482
pmcid: 3651129
Yadav, A. B. et al. Inhalable microparticles containing isoniazid and rifabutin target macrophages and ‘stimulate the phagocyte’ to achieve high efficacy. Indian J. Exp. Biol. 47(6), 469–474 (2009).
pubmed: 19634713